The colorectal cancer market was valued at USD 15.68 Billion in 2025, driven by the increasing prevalence of colorectal cancer and the growth in clinical trials across the 8 major markets. The market is expected to grow at a CAGR of 7.80% during the forecast period of 2026-2035, with the values likely to reach USD 33.23 Billion by 2035.
Base Year
Historical Period
Forecast Period
The increasing cases of colorectal cancer along with the growing aging population is one of the primary factors contributing to the market growth.
The rising development of non-invasive screening methods, such as liquid biopsies and stool-based DNA tests is a significant market trend.
The growth in clinical trials evaluating new treatment options, increased focus on colorectal cancer screening, and robust government support for cancer research are anticipated to shape the market landscape.
Compound Annual Growth Rate
7.8%
Value in USD Billion
2026-2035
*this image is indicative*
Colorectal cancer develops in the tissues of the colon or rectum, located at the lower end of the digestive tract. It is estimated that 1 in 24 individuals are likely to develop the disease in their lifetime. Although counted as one of the most treatable diseases when caught in the early stages, colorectal cancer is considered the leading cause of cancer-related deaths in men. The rising incidence of colorectal cancer along with the increasing aging population is one of the primary factors contributing to the market growth. Increased regular screening programs and advancements in imaging techniques are also supporting the market expansion. Moreover, the rising introduction of targeted therapies, the shift towards combination therapies, and the growth in clinical trials evaluating new treatment options are poised to influence the market dynamics.
Increasing Prevalence of Colorectal Cancer is Driving Market Growth
According to the American Cancer Society (ACS), around 152,810 new cases of colorectal cancer are estimated to occur in 2024 in the United States, out of which 81,540 cases are predicted to be of men and 71,270 cases will account for women. Further, colorectal cancer is reported as the second-leading cause of all cancer-related deaths in the country and is estimated to be responsible for 53,010 deaths. This increasing burden of colorectal cancer as a result of the growing aging populations and unhealthy lifestyle patterns is expected to fuel market growth.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
Market Breakup by Cancer Type
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on Cancer Type Represents Significant Market Share
The market segmentation by cancer type includes colorectal cancer adenocarcinoma and gastrointestinal carcinoid tumors, among others. Adenocarcinoma accounts for the majority of cases of colorectal cancer, originating in the glandular cells lining the inside of the colon and rectum. Early-stage adenocarcinoma is usually treated with surgery, but combination treatments are often needed to manage advanced cases. The rising availability of targeted therapies like bevacizumab (Avastin) and cetuximab (Erbitux) and immunotherapies like pembrolizumab (Keytruda) is projected to support the growth of this segment in the forecast period.
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share owing to the high incidence rate of colorectal cancer which drives the demand for screening, diagnostics, and therapies. The easy availability of advanced treatments including immunotherapies, targeted therapies, and advanced surgical techniques also supports the market growth. Moreover, increasing investments in clinical research and trials along with rising cancer screening initiatives are anticipated to propel the market expansion in the country.
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
AstraZeneca, headquartered in Cambridge, United Kingdom, is a global, science-led biopharmaceutical business that is actively involved in developing immunotherapy drugs and targeted therapies for various cancers. Its drug candidate AZD-9592 is under clinical development and currently undergoing Phase I trial for metastatic colorectal cancer.
Pfizer is one of the leading players in the market with a strong presence in the oncology sector. Its oral small molecule kinase inhibitor BRAFTOVI® (encorafenib) in combination with cetuximab (ERBITUX®) is approved by the FDA for previously treated metastatic colorectal cancer with a BRAFV600E mutation in adult patients.
Swiss multinational pharmaceutical company Novartis is focused on the development of targeted therapies that target specific cancer growth pathways. The company is actively investing in several clinical programs to test new agents and combination therapies for colorectal cancer. Novartis' drug candidate Gevokizumab (XOMA-052), a human-engineered IgG2 monoclonal antibody, is under clinical development for metastatic colorectal cancer.
Amgen, headquartered in Thousand Oaks, California, has a dominant presence in the market and is well known for developing innovative human therapeutics for diseases with high unmet medical needs. The company is focusing on expanding its biosimilar portfolio to improve the accessibility and affordability of effective treatments.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include F. Hoffmann-La Roche Ltd., GSK plc, Eli Lilly and Company, AbbVie Inc., and Teva Pharmaceuticals Ltd.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Cancer Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share